Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267267 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,784
- Enrollment target
NCT00267267 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,784 participants.
The verdict
NCT00267267, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,784 participants
- Enrollment target
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.
Interventions
- DRUG torcetrapib/atorvastatin
- DRUG ezetimibe/simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,784 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267267
The ClinicalTrials.gov registry entry for NCT00267267 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,784 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which torcetrapib/atorvastatin is the first listed.
NCT00267267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267267 about?
NCT00267267 is a clinical study titled "A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.
What is the current status of trial NCT00267267?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,784 participants. The study started on 2006-01. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00267267?
The interventions under investigation include: torcetrapib/atorvastatin (DRUG), ezetimibe/simvastatin (DRUG).
Who is sponsoring clinical trial NCT00267267?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.